Search

Displaying results 711 - 720 of 4339 in total
  1. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    [A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning.

  2. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    , marketed by Astellas under the brand Cresemba. … Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis

  3. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation

  4. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.

  5. Drug

    Human thrombin

    go.drugbank.com/drugs/DB11571
    ApprovedInvestigational

    Furthermore, human thrombin is manufactured by chromatographic purification of prothrombin from cryo-poor plasma followed by activation with calcium chloride [FDA Label]. … Thrombin is a highly specific serine protease encoded by the F2 gene that transforms soluble fibrinogen into insoluble fibrin.

  6. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    [A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor. … Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.

  7. Drug

    Meradimate

    go.drugbank.com/drugs/DB11096
    Approved

    Meradimate is approved by the FDA and Health Canada to be used as an ingredient in sunblocking products.[L1113, L2748]

    Mixtures: Body Armor Sun 'n Bug Block
  8. Drug

    Trimethobenzamide

    go.drugbank.com/drugs/DB00662
    ApprovedInvestigational

    Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). … In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

  9. Drug

    Pemirolast

    go.drugbank.com/drugs/DB00885
    ApprovedWithdrawn

    As an ophthalmic aqueous sterile solution, pemirolast is used for the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis.

  10. Drug

    Cobicistat

    go.drugbank.com/drugs/DB09065
    ApprovedInvestigational

    agents that are metabolized by CYP3A enzymes. … Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered

    Mixtures: GENVOYA 150MG/150MG/200MG/10MG FILM KAPLI TABLET, 90 ADET, GENVOYA 150MG/150MG/200MG/10MG FILM KAPLI TABLET, 30 ADET